PANCREATIC DUCTAL ADENOCARCINOMA

This study tests whether using a special surgical glue (Glubran 2) during pancreas surgery can reduce the risk of a dangerous leak from the pancreas. About 194 adults with a soft pancreas who need surgery for cancer will be randomly assigned to receive the glue or standard care. …

This study is for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It tests a new drug called JPI-547 given together with standard chemotherapy. The goal is to find the best dose and see if the combination is safe and helps shrink or control…

This study tests a new approach for people with advanced pancreatic cancer that cannot be removed by surgery. The treatment combines a procedure that uses heat to destroy tumor cells (radiofrequency ablation) with an immunotherapy drug (pembrolizumab) and standard chemotherapy. T…

This study tests an experimental drug called ART0380, taken as a pill, for people with advanced or metastatic solid tumors (cancers that have spread). The goal is to find a safe dose and see if it works alone or with standard chemotherapies (gemcitabine or irinotecan). About 442 …

This early-stage study tests a new treatment using a patient's own immune cells, modified in a lab to recognize and attack cancer cells with a specific KRAS mutation (G12D). It is for adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have not respond…

This study tests an experimental drug, LY3962673, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and see if it can shrink tumors, both alone and…

This study tests whether adding drugs that block the tumor's ability to hide from the immune system can make radiation therapy work better before surgery for advanced pancreatic cancer. About 60 people will receive standard radiation plus an immunotherapy drug, with or without tw…

This study tests a more thorough surgery called total mesopancreas excision for people with pancreatic head cancer. The goal is to remove all cancer tissue around the pancreas to lower the chance of the cancer returning. 90 adults with resectable cancer will be followed for 2 yea…

This study tests whether adding a medical glue (Glubran 2) to the standard surgical connection after pancreas tumor removal can reduce the risk of a dangerous leak called pancreatic fistula. About 100 adults having this surgery will be randomly assigned to receive either the stan…

This early-phase trial tests a new medicine, BI 765049, in adults with advanced colorectal, stomach, or pancreatic cancer that cannot be removed by surgery or has spread. The main goal is to find the highest safe dose and best way to give the drug. BI 765049 is designed to help t…

This early-phase study tests a new drug called AZD4360 in adults with advanced stomach, bile duct, or pancreatic cancers that have not responded to prior treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 117 participa…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety. About 10 participants will receive one of two dose lev…

This study tests a new drug called AZD0901, alone or with other cancer drugs, in people with advanced solid tumors that have a specific marker (CLDN18.2). The goal is to see if it is safe and shrinks tumors. About 224 adults with stomach, bile duct, or pancreatic cancer will take…

This study tests two experimental drugs, elironrasib and daraxonrasib, alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if these drugs are safe and can shrink or control tumors. About 534 adults with lung, colorec…

This study tests whether adding the experimental drug BMS-986504 to standard chemotherapy helps people with a specific type of advanced pancreatic cancer live longer or slow tumor growth. It is for patients whose tumors have a missing MTAP gene. About 470 participants will receiv…

This study is testing several new experimental drugs called RAS(ON) inhibitors, alone or with standard chemotherapy, in people with advanced colorectal or pancreatic cancer that has spread. About 1,130 adults will participate to see if these combinations are safe and can shrink t…

This study tests a device that sends low-intensity electric fields (TTFields) to tumors, combined with standard chemotherapy, in people with metastatic pancreatic cancer. The goal is to see if adding the device is safe and helps control the disease. About 30 adults will take part…

This early study tests a new drug, ASP2138, given as a shot two weeks before surgery for people with a type of pancreatic cancer that has a specific protein (CLDN18.2). After surgery, patients receive standard chemotherapy for up to six months. The main goal is to check safety an…

This study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or not responded to standard therapy. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest dose, un…

This early-phase study tests a new treatment for people with advanced pancreatic cancer that has a specific KRAS G12D mutation. The treatment uses tiny particles called exosomes to deliver a molecule that blocks the cancer-driving gene. The study aims to find the best dose and ch…

This early-stage study tests an experimental drug called PF-08046050 in people with advanced solid tumors that have come back or not improved with standard treatments. The drug is designed to attach to cancer cells and kill them. The main goal is to check safety and find the righ…

This early-stage study tests a new radioactive drug, [177Lu]Lu-NNS309, in adults with advanced pancreatic, lung, breast, or colorectal cancers that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink t…

This study tests a new drug called MK-2870, alone or with other cancer treatments, in people with advanced colorectal, pancreatic, or bile duct cancers that have spread or can't be removed by surgery. The main goals are to check the drug's safety and see if it can shrink tumors. …

This program provides early access to an experimental immunotherapy called ELI-002 7P for people with a specific type of pancreatic cancer (KRAS/NRAS-mutated) who have had their tumor removed but are at high risk of the cancer coming back. It is for patients who have no other tre…

This study compares two surgical methods for removing pancreatic or nearby tumors: laparoscopic (keyhole) surgery and open surgery. The goal is to see which approach has fewer complications and better outcomes. About 90 adults with resectable tumors will take part, and researcher…

This early-stage trial tests a new radioactive drug, [225Ac]-FPI-2068, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and see how the drug spreads in the body. About 70 people with cancers like lung, colon, …

This study tests a new drug called PT886 in people with advanced stomach, pancreatic, or bile duct cancers that cannot be removed by surgery or have spread. The trial has two parts: first, finding the safest dose of PT886 alone, then testing it combined with chemotherapy or immun…

This early-phase study is testing an experimental drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and find the right dose. About 96 …

This study tests a new treatment for people with advanced pancreatic cancer whose tumors have a specific genetic change (KRAS G12V) and a certain immune type (HLA-A*11:01). The treatment uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells. …

This early-stage trial is testing a new treatment for people with metastatic pancreatic or breast cancer that has spread. The treatment combines chemotherapy drugs with high-dose vitamin C and the patient's own stem cells to try to overcome drug resistance. The main goal is to ch…

This study tests an experimental drug called AZD5863 in adults with advanced stomach, esophageal, or pancreatic cancers that have spread. The drug is designed to help the body's immune cells attack cancer cells. The main goals are to check safety and see if the drug can shrink tu…

This early-phase study tests a new drug called PTM-101 given alongside standard chemotherapy for people with pancreatic cancer that is borderline resectable or locally advanced (not yet spread to distant organs). The goal is to see if adding PTM-101 is safe and can shrink tumors …

This study tests a new way of giving chemotherapy to people with metastatic pancreatic cancer. Instead of one standard regimen, patients will receive two different chemo combinations (NALIRIFOX and GnP) in alternating months. The goal is to see if this approach helps keep the can…

This study tests a new oral drug, IPN01194, in adults with advanced solid tumors (melanoma, colorectal, pancreatic, or head and neck cancers) that have not responded to standard treatments. The goal is to find the right dose and check if the drug is safe and can shrink tumors. Ab…

This early-stage study tests a new drug (177Lu-DFC413) that delivers radiation directly to cancer cells in adults with advanced solid tumors, including pancreatic, lung, breast, colorectal, and soft tissue cancers. The main goals are to check safety, find the right dose, and see …

This study tests a new drug, ASP5834, for people with advanced solid tumors that have certain changes in the KRAS gene. The drug is given alone or with another drug (panitumumab) for colorectal cancer. The main goals are to find a safe dose and check for side effects. About 364 a…

This study tests whether a combination of two immune-boosting drugs (odetiglucan and mitazalimab) can help control pancreatic cancer that cannot be removed by surgery. About 100 adults whose cancer has not worsened after 4-6 months of standard chemotherapy will receive the treatm…

This study is testing a new treatment that uses a radioactive substance to target and destroy cancer cells in people with advanced solid tumors (like pancreatic, stomach, or ovarian cancer) that have not responded to standard treatments. The therapy works by attaching to a protei…

This study tests a new oral drug, VS-7375, in people with advanced solid tumors (like pancreatic, lung, or colorectal cancer) that have a specific KRAS G12D mutation. The trial will first find the safest dose, then check if the drug shrinks tumors when used alone or with other ca…

This early-phase trial tests a new drug called JANX008 in adults with advanced solid tumors (like lung, kidney, breast, or colorectal cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shri…

This study is looking for 20,000 people who have a family history of pancreatic cancer or carry certain gene changes that raise their risk. The goal is to find better ways to detect pancreatic cancer early, when it's easier to treat. Participants will be followed over time to see…

This study tests whether an MRI scan can find very small liver tumors that standard CT scans miss in people newly diagnosed with pancreatic cancer. About 120 adults will get both a CT and an MRI before any treatment. If MRI proves better at spotting these hidden tumors, doctors c…

This study tests a special MRI scan that uses an experimental contrast agent called hyperpolarized carbon-13 pyruvate. Unlike standard MRI, this scan shows how tumors process nutrients, which may help doctors predict whether pancreatic cancer treatments are working. The study inv…

This study tests a new PET/CT scan using an investigational agent (GEH300079) to detect peritoneal carcinomatosis—cancer spread in the lining of the abdomen—in people with colorectal, gastric, ovarian, or pancreatic cancers. About 175 adults with known or suspected spread will re…

This study is testing a new blood test that looks for tiny particles called exosomes to find pancreatic cancer early. The goal is to see if this test can accurately detect the disease in 2000 adults, including those with and without cancer. If successful, it could lead to a simpl…

This study tests a new imaging agent called [18F]FPyQCP for PET scans to better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the agent and undergo PET/CT imaging. The goal is to see if it i…

This study is testing whether a new PET imaging tracer called [18F]FAPI-74 can find tumors as well as or better than the standard tracer in adults with certain cancers (like pancreatic, ovarian, or lung cancer). Participants will get both types of scans to compare how many tumors…

This early-phase study is testing a new substance called RAD301 to see how it moves through the body and how much radiation it gives off. It involves 9 people: healthy volunteers and patients with certain cancers like pancreatic, lung, or ovarian cancer. The goal is to measure sa…

This study looks at whether a simple blood test that measures tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is shrinking a patient's pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to see if treatment is working. The goal is to see if the blo…

This study looks at whether genetic information from tumors can help doctors choose better treatments for pancreatic cancer. About 200 adults with early or locally advanced pancreatic cancer will give blood, tissue, and fluid samples for genetic testing. Researchers want to see i…

This study is for people at high risk of pancreatic cancer, such as those with a strong family history or certain genetic conditions. Researchers will use MRI scans and endoscopic ultrasound to look for early signs of the disease. The goal is to find cancer sooner, when it may be…

This study tests a new screening program for people at high risk of pancreatic cancer. Participants aged 50-85 with recent diabetes and a high risk score will get regular CT scans analyzed by artificial intelligence, plus blood tests. The goal is to see if this approach is practi…

This study follows 4,000 adults with pancreatic cysts to learn which ones turn into cancer and which stay harmless. Participants provide health updates over time, but no treatment is given. The goal is to help doctors decide when surgery is needed and when it can be safely avoide…

This study enrolls 5,000 people at high risk for pancreatic cancer to collect blood, pancreatic juice, and medical images over 10 years. Researchers will use these samples to develop and validate tests for early detection, including AI-assisted analysis. Participants must be 18 o…

This study is developing a blood test that looks at tiny particles called exosomes to predict how well pancreatic cancer will respond to chemotherapy given before surgery. Researchers will analyze blood samples from 200 patients who have already had chemotherapy and surgery. The …